(HQY) HealthEquity - Ratings and Ratios
Exchange: NASDAQ • Country: United States • Currency: USD • Type: Common Stock • ISIN: US42226A1079
HQY EPS (Earnings per Share)
HQY Revenue
HQY: HSA, FSA, Investment Platform, COBRA Services, Commuter Benefits
HealthEquity, Inc. is a technology-driven company that offers a suite of services enabling consumers and employers to manage health care expenses and benefits. The companys platform includes health savings accounts, investment services, and automated investment advisory tools, catering to the growing demand for personalized health care management. By serving both individuals and employers directly, as well as through a network of health plans, benefits administrators, and brokers, HealthEquity has established itself as a significant player in the U.S. health care technology sector.
Analyzing the companys position and trajectory involves understanding its market presence and financial health. With a market capitalization of $9.745 billion, HealthEquity operates within the Managed Health Care sub-industry, indicating its substantial scale and influence. The companys price-to-earnings ratio stands at 82.87, with a forward P/E of 31.85, suggesting that while the current earnings might be perceived as high compared to the stock price, future earnings are expected to improve, potentially aligning the stocks valuation more closely with industry norms.
From a technical analysis perspective, the stocks recent performance indicates a positive trend. With a last price of $111.55, it is above its 20-day, 50-day, and 200-day Simple Moving Averages (SMA20, SMA50, SMA200), signaling a bullish trend. The Average True Range (ATR) of 3.50, or 3.14%, suggests moderate volatility. Given the 52-week high and low of $114.51 and $67.98, respectively, the stock is near its peak, indicating strong recent performance but also potential for consolidation or correction.
Forecasting the future performance of HQY involves integrating both technical and fundamental insights. Based on the bullish trend indicated by the SMA analysis and the companys strong market position, it is plausible that HealthEquity could continue to grow. However, the high P/E ratio suggests that the stocks current price may be justified by expectations of future growth rather than current earnings. If the company can meet or exceed the expectations reflected in its forward P/E of 31.85, the stock could see further gains. Conversely, failure to meet these expectations could lead to a correction. Therefore, a potential forecast is that HQY could see a moderate increase, potentially reaching $120 in the near term if it maintains its current trend and meets market expectations, though this would depend on various factors including overall market conditions and the companys ability to continue its growth trajectory.
Additional Sources for HQY Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle
HQY Stock Overview
Market Cap in USD | 9,059m |
Sector | Healthcare |
Industry | Health Information Services |
GiC Sub-Industry | Managed Health Care |
IPO / Inception | 2014-07-31 |
HQY Stock Ratings
Growth Rating | 49.1 |
Fundamental | 25.5 |
Dividend Rating | 0.0 |
Rel. Strength | 30.8 |
Analysts | 4.57 of 5 |
Fair Price Momentum | 99.87 USD |
Fair Price DCF | 14.00 USD |
HQY Dividends
Currently no dividends paidHQY Growth Ratios
Growth Correlation 3m | 72.4% |
Growth Correlation 12m | 62.8% |
Growth Correlation 5y | 57.8% |
CAGR 5y | 11.44% |
CAGR/Max DD 5y | 0.20 |
Sharpe Ratio 12m | 0.58 |
Alpha | 14.14 |
Beta | 1.042 |
Volatility | 43.74% |
Current Volume | 854.5k |
Average Volume 20d | 998.3k |
As of June 16, 2025, the stock is trading at USD 104.76 with a total of 854,492 shares traded.
Over the past week, the price has changed by -5.76%, over one month by +7.28%, over three months by +4.01% and over the past year by +24.17%.
Neither. Based on ValueRay´s Fundamental Analyses, HealthEquity is currently (June 2025) neither a good nor a bad stock to buy. It has a ValueRay Fundamental Rating of 25.51 and therefor a neutral outlook according to the companies health.
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of HQY is around 99.87 USD . This means that HQY is currently overvalued and has a potential downside of -4.67%.
HealthEquity has received a consensus analysts rating of 4.57. Therefor, it is recommend to buy HQY.
- Strong Buy: 9
- Buy: 4
- Hold: 1
- Sell: 0
- Strong Sell: 0
According to our own proprietary Forecast Model, HQY HealthEquity will be worth about 113.5 in June 2026. The stock is currently trading at 104.76. This means that the stock has a potential upside of +8.31%.
Issuer | Target | Up/Down from current |
---|---|---|
Wallstreet Target Price | 121.7 | 16.2% |
Analysts Target Price | 121.7 | 16.2% |
ValueRay Target Price | 113.5 | 8.3% |